Merck’s acquisition strategy clearly reflects its commitment to constructing a portfolio extending beyond oncology. For instance, the recent $680 million acquisition of Harpoon Therapeutics ...

The simplicity of the new monoclonal Enflonsia could give it an advantage over AstraZeneca’s Beyfortus Enflonsia, a monoclonal antibody for RSV, is approved for use in children under 12 months ...

CDC vaccine advisers recommend Merck’s RSV therapy for babies The vote was the first for the new members of the committee, who had been handpicked by health secretary Robert F. Kennedy Jr.

Once commercially launched, Merck’s Enflonsia will face stiff competition from AstraZeneca AZN/ Sanofi ’s SNY RSV antibody Beyfortus, which was also approved for a similar indication in 2023.

Editor’s note: This story was updated at 8:47 a.m. June 19, 2025, to note that Merck Manuals – a separate entity from Merck – launched the new tool.

News Nation RFK Jr.’s advisers back Merck’s RSV shot for newborns June 26, 2025 Updated Thu., June 26, 2025 at 12:50 p.m. A machine adds RSV adjuvant to a vaccine vial along a production line ...

RAHWAY, N.J.--(BUSINESS WIRE)-- Merck (MRK), known as MSD outside of the United States and Canada, will hold its second-quarter 2025 sales and earnings conference call with institutional investors ...

The votes in favor of Merck’s shot are a sigh of relief after Kennedy gutted the panel and tapped replacements, some of whom are well-known vaccine critics.

Merck & Co.’s ambition to get the first oral PCSK9 inhibitor to market came one step closer this morning as the pharma unveiled a pair of phase 3 wins for enlicitide decanoate in patients with ...

By Meg Tirrell, CNN (CNN) — A group of outside advisers to the US Centers for Disease Control and Prevention voted 5-2 to recommend the use of a new shot that can protect babies from respiratory ...

Merck & Co., Inc. (NYSE:MRK) is one of the best wide moat stocks to buy now. On June 9, Merck’s preventative antibody shot received authorization from the U.S. Food and Drug Administration (FDA).

U.S. FDA Approves Merck’s ENFLONSIA™ (clesrovimab-cfor) for Prevention of Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease in Infants Born During or Entering Their First RSV ...